The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Join ShareProphets at less than 2p per article

> Hot share tips

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

Jim Mellon’s Regent Pacific buys Plethora at 12.5p a share but…

By Tom Winnifrith | Wednesday 4 November 2015

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

This is a bolt from the blue. Regent Pacific a HK and Frankfurt listed investment company run by my good friend Jim Mellon has today announced an all paper offer for AIM listed Plethora (PLE) at 12.5p a share. But hang on, the devil is in the detail.

Jim, Regent Pacific and others already own just under 30% of Plethora and today’s statement makes it clear – as I have warned repeatedly – that a cash crunch was looming.

"For the six months ended 30 June 2015, Plethora made a loss of £493,000 (or approximately HK$5.9million) and had a cash balance as at 30 June 2015 of £2.8 million (or approximately HK$33.4 million).As at 30 October 2015, the financial records of Plethora stated that the cash balance was approximately £1 million (or approximately HK$11 million).Current Plethora expectations are that commercial operations under its current operating plans will face a significant negative impact in January 2016 in the absence of further funding being available to Plethora.


The collapse in the Plethora share price would have made a fund raising a tough ask. And so Jim has solved the problem. Regent Pacific has net assets last stated of cUS49 million and net cash of cUS$13 million. It can therefore fund Plethora to the point where its premature ejaculation product bursts onto the market. Jim is taking a big bet on this.

The purchase is in Regent shares at HK0.095. At one level Jim has pitched the offer at an incredibly generous level. It is massive premium to the last share price (sub 3p) and also to the price of the last funding (9p). You cannot fault him on this at all.

But be aware that with Regent shares having fallen from HK0.43 five years ago to HK0.095 last night the company is capitalised at just £30 million – roughly speaking NAV. The Plethora offer will be worth £122 million. Okay Jim et al own c30% but that still leaves £86 million worth of Plethora shareholders then owning stock in an HK listed company and one imagines that a fair few of them will be wanting to sell. Apart from anything else the Regent will – following this deal – be valued (at HK$0.05) at £152 million and will have net assets of c£27 million (Plethora has negative net assets).  Suddenly Regent is a highly geared play on the success of the Premature Ejaculation drug .PSD502

As such you rather suspect that the HK share price will drift pretty sharpish from the current level. So it is no shock that Plethora shares still trade at a 7p mid not at the 12.5p paper value.

In conclusion, hat’s off to Jim for making this offer. It is probably the best way out. But until we see how big the selling pressure is in HK post the deal it is hard to say where the shares will go.

No doubt Jim will be covering this in his keynote talk at Gold and Bears on November 28.

Remember to get your free ticket to hear from Jim and the other top speakers on 28 November at Gold & Bears enter the promotional code SPGB25 when booking HERE - tickets will be sent out within 24 hours of order.

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on PLE



  1. The difference between Jim’s outfit and other small pharma/biotechs is that the drug PSD502 has already been proven to work at phase III. PLE just has to raise enough cash for the regulatory stuff/marketing so it can be sold.

    It is a fair offer for the company. But ISA holders can not keep foreign shares in their account.

  2. Anaylist – except the product is poor mans coke in a spray …

    If this product was even needed (baring in mind it only helps someone last a few seconds longer) do you not think the little blue pill makers would have been all over it some time ago… Oh wait they kind of were because Viagra also makes people last longer.

    There are pills being developed ATM for this very purpose…

    Can you really see a little spray with poor mans coke in you spray on the end of your bellend taking off as a product ?..

    Regardless of it’s got the all clear from EU who in their right mind will use it ?… The ideas good, the products terible!

    I know the company very well as I was in from 2p before the pump and mark my words no matter what happens here JM won’t lose any money, it’s a safe bet, for him and for him only!

  3. Czech Mate (aka Janos)

    ISA holders most certainly CAN keep foreign shares in their account.

    The only condition (roughly speaking) is that the shares are listed on a recognised stock exchange.

  4. Its a shrewd move, it takes out the 15 warrants and confirms that the reduced fill issue is resolved – why else would RP buy out the royalties for £2.4 million a few months ago and now offer 12.5 p in stock. Ple spiked at 20 p on the back of the Recordati deal and we know that two further licensing deals are already line up pending variation approval on the cannister size. Add to that potential in US and Asia and RP will be getting this on the cheap.

    Camptire – you need to look at the medical read outs and do a little basic research before making such silly comments.

Enter your comment below. Fields marked * are required. You must preview your comment first before finally posting.

Site by Everywhen